… of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial …
1. 请及时下载文件确认是否正确, 系统将在 2025-06-20 14:15:33 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
KA Papp, RG Langley, M Lebwohl, GG Krueger…
The Lancet, 2008
thelancet.com
… against interleukins 12 and 23, has shown therapeutic potential for psoriasis. This study assessed the efficacy and safety of ustekinumab in psoriasis patients and assessed dosing …